×
About 3,770 results

ALLMedicine Generalized Tonic-clonic Seizures Center

Research & Reviews  857 results

The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a ...
https://doi.org/10.1016/j.jns.2020.116903
Journal of the Neurological Sciences; Pascarella A, Iannone LF et. al.

May 24th, 2020 - Perampanel (PER) is a novel antiepileptic drug approved as an add-on therapy for focal onset seizures with or without generalization and primary generalized tonic-clonic seizures. Aim of this study was to evaluate PER efficacy and tolerability as ...

GABRG2 Deletion Linked to Genetic Epilepsy with Febrile Seizures Plus Affects the Expre...
https://doi.org/10.1016/j.neuroscience.2020.04.049
Neuroscience Li X, Guo S et. al.

May 18th, 2020 - Mutations in γ-aminobutyric acid A receptor (GABAA) subunits and sodium channel genes, especially GABRG2 and SCN1A, have been reported to be associated with febrile seizures (FS) and genetic epilepsy with febrile seizures plus (GEFS+). GEFS+ is a ...

Ictal quantitative surface electromyography correlates with postictal EEG suppression.
https://doi.org/10.1212/WNL.0000000000009492
Neurology Arbune AA, Conradsen I et. al.

May 11th, 2020 - To test the hypothesis that neurophysiologic biomarkers of muscle activation during convulsive seizures reveal seizure severity and to determine whether automatically computed surface EMG parameters during seizures can predict postictal generalize...

Adult-onset subacute sclerosing panencephalitis presenting with tonic motor seizures.
https://doi.org/10.1080/00207454.2020.1759584
The International Journal of Neuroscience; Yagcioglu Yassa O, Kenangil G et. al.

May 5th, 2020 - Purpose/aim of the study: Subacute sclerosing panencephalitis (SSPE) is a degenerative disease of the brain caused by a persistent measles virus infection occurring mostly in childhood or early adolescence. The spectrum of epileptic phenomena asso...

Post-Traumatic Status Epilepticus Masquerading as Acute Ischemic Stroke: A Case Report ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213816
The American Journal of Case Reports; Panagopoulos D, Markogiannakis G et. al.

May 4th, 2020 - BACKGROUND Advanced imaging is one of the main modalities utilized in the diagnostic investigation of a first-time epileptic ictus, as well as in the evaluation of a patient suspected of having an ischemic stroke. CASE REPORT We report the case of...

see more →

Guidelines  2 results

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic d...
https://doi.org/10.1212/WNL.0000000000005755
Neurology Kanner AM, Ashman E et. al.

Jun 14th, 2018 - To update the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). The 2004 AAN criteria were used to systematically review literature...

CARNEXIV™ (carbamazepine) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206030s000lbl.pdf

CARNEXIV is indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types

see more →

Drugs  971 results see all →

Clinicaltrials.gov  1,867 results

Carbamazepine er - carbamazepine tablet, extended release-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f6f568d-174d-49d6-a319-3b1a541e92b2

May 25th, 2020 - Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizu...

Subvenite - lamotrigine tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf48426a-c9b8-49b7-98fd-3407a3b28d0b

May 25th, 2020 - SUBVENITE is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1) Epilepsy—monotherapy in patients...

The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a ...
https://doi.org/10.1016/j.jns.2020.116903
Journal of the Neurological Sciences; Pascarella A, Iannone LF et. al.

May 24th, 2020 - Perampanel (PER) is a novel antiepileptic drug approved as an add-on therapy for focal onset seizures with or without generalization and primary generalized tonic-clonic seizures. Aim of this study was to evaluate PER efficacy and tolerability as ...

Lamotrigine - lamotrigine tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=488ffa59-687f-4e44-b391-81361312726d

May 21st, 2020 - Lamotrigine, USP is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in pa...

Levetiracetam - levetiracetam tablet, film coated-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc8b413f-2f07-4e6a-bb8e-a1f2119ae1cf

May 21st, 2020 - Levetiracetam tablet is indicated for adjunctive therapy in the treatment of: • Partial onset seizures in patients one month of age and older with epilepsy (1.1) • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic ep...

see more →

News  73 results

Little Evidence to Support Treatments for Prevention of Sudden Unexpected Death in Epilepsy
https://www.medscape.com/viewarticle/928854

Apr 16th, 2020 - NEW YORK (Reuters Health) - More research is needed to identify effective interventions aimed at preventing sudden unexpected death in patients with epilepsy (SUDEP), according to an updated Cochrane review. SUDEP occurs with an incidence of 1 to ...

FDA Clears Epilepsy Smartwatch for Use in Children
https://www.medscape.com/viewarticle/907432

Jan 8th, 2019 - The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smartwatch (Empatica Inc) for seizure tracking in children as young as age 6. The Embrace smartwatch detects patterns in motion and physiological signals that may be a...

SUDEP risk may change over time
https://www.mdedge.com/jcomjournal/article/189912/epilepsy-seizures/sudep-risk-may-change-over-time?channel=53
Erik Greb

Nov 27th, 2018 - NEW ORLEANS – Risk for sudden unexpected death in epilepsy (SUDEP) may change over time and yearly patient risk assessments are advisable, based on study results presented at the annual meeting of the American Epilepsy Society. Based on 3 years of.

FDA Expands Use of Epilepsy Drug Perampanel (Fycompa) to Younger Children
https://www.medscape.com/viewarticle/902760

Sep 30th, 2018 - The US Food and Drug Administration (FDA) has granted expanded approval of perampanel (Fycompa, Esai Inc) for the treatment of "partial-onset seizures (POS) with or without secondary generalized seizures" in patients as young as 4 years, the manuf...

Long-Term Perampanel Treatment Is Safe and Effective for Adolescents
https://www.mdedge.com/neurology/epilepsyresourcecenter/article/163951/epilepsy-seizures/long-term-perampanel

Apr 23rd, 2018 - LOS ANGELES—Treatment for as long as four years with adjunctive perampanel is safe and effective for adolescents with secondarily generalized seizures or primary generalized tonic-clonic seizures, according to a post hoc study presented at the 70t.

see more →